Recent News and Upcoming Events

Recent News

• July 1, 2020

  Aspira Women’s Health Inc. Announces Equity Financing of Approximately $11 Million

  For a pdf of this press release please click here AUSTIN, Texas, July 1, 2020 — Aspira Women’s Health Inc. (Nasdaq: AWH) (“ASPIRA”), a bioanalytical-based women’s health company focused on gynecologic disease, today announced that investors, including certain affiliates of Jack W. Schuler, ASPIRA’s largest stockholder, have agreed to purchase approximately $11 million of unregistered shares…

• June 29, 2020

  Aspira Women’s Health, Inc. Announces First Patient Enrolled in Prospective OVANex Study for Benign Pelvic Mass Monitoring

  For a pdf of this press release please click here AUSTIN, Texas — June 29, 2020 — Aspira Women’s Health, Inc. (Nasdaq: AWH), a bioanalytical-based women’s health company, today announced the first patient enrolled in a national clinical study of benign pelvic mass management. The study will enroll over 1,000 women for assessing ovarian cancer…

• June 11, 2020

  Vermillion, Inc. Announces Rebranding and Company Name Change to Aspira Women’s Health Inc.

  For a pdf of this press release please click here AUSTIN, Texas — June 11, 2020 — Vermillion, Inc. (Nasdaq: VRML), a bioanalytical-based women’s health company focused on ovarian cancer risk assessment, today announced a major rebranding to reflect the company’s continuing evolution towards becoming a comprehensive gynecologic health company, including a corporate name change…

• June 10, 2020

  Vermillion Completes Validation of New Pre-Surgical Test Offerings with OVA1®plus, including COVID-19 Antibody Testing and Additional Pelvic Mass Risk Assessment Biomarkers

  For a pdf of this press release please click here AUSTIN, Texas — June 10, 2020 — Vermillion, Inc. (Nasdaq: VRML), a bioanalytical-based women’s health company focused on gynecologic disease, is excited to announce that its wholly-owned subsidiary ASPIRA Labs has completed laboratory validation of the Roche Elecsys Anti-SARS-CoV-2 antibody test for detecting the presence…

• June 10, 2020

  Vermillion Set to Join Russell 3000 Index

  For a pdf of this press release please click here AUSTIN, Texas — June 9, 2020 — Vermillion, Inc. (Nasdaq: VRML), a bioanalytical-based women’s health company focused on gynecologic disease, today announced that it is set to join the broad-market Russell 3000(R) Index at the conclusion of the 2020 Russell indexes annual reconstitution, effective after…